Company news

BioCryst Pharmaceuticals, Inc. news in 2023

BioCryst Pharmaceuticals, Inc.'s news releases, calls and decks from 2023, newest first.

View company

BioCryst Announces Publication of Data from Open-label Extension of the APeX-2 Pivotal Trial of ORLADEYO® (berotralstat)

December 18, 2023

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the National Administration of Drugs, Foods, and Medical Devices (ANMAT) in Argentina

November 28, 2023

BioCryst Launches ORLADEYO® (berotralstat) in Spain

November 20, 2023

BioCryst Presents New Real-world Data Showing Reduced Attack Rates in Patients with HAE with Normal C1-inhibitor Following Long-term Treatment with ORLADEYO® (berotralstat)

November 9, 2023

BioCryst R&D Day Highlights New Diversified Pipeline of First-in-Class/Best-in-Class Therapies with Five Programs Expected in Clinical Development in Next 24 Months

November 2, 2023

BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside’s Proprietary SCS Microinjector®

November 2, 2023

BioCryst Reports Third Quarter 2023 Financial Results and Provides Business Update

November 1, 2023

BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology

October 26, 2023

BioCryst Begins Enrollment in Proof-of-Concept Trial to Confirm Safe, Effective, Once-daily Dose of Oral Factor D Inhibitor, BCX10013

October 25, 2023

BioCryst to Host R&D Day on November 3

October 19, 2023

BioCryst to Report Third Quarter 2023 Financial Results on November 2

October 18, 2023

INESSS Recommends Public Reimbursement for BioCryst’s ORLADEYO® (berotralstat) for the Prevention of Attacks for Hereditary Angioedema Patients in Québec

September 17, 2023

BioCryst Reports Second Quarter 2023 Financial Results and Provides Business Update

August 2, 2023

BioCryst to Report Second Quarter 2023 Financial Results on August 3

July 19, 2023

BioCryst Selects Er-Kim Pharmaceuticals as Commercial Partner for ORLADEYO® (berotralstat) in Turkey

July 18, 2023

BioCryst to Participate in the 2023 US HAEA National Summit

July 16, 2023

BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 European Academy of Allergy and Clinical Immunology Congress

May 30, 2023

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Public Health Institute of Chile

May 21, 2023

BioCryst Reports First Quarter 2023 Financial Results and Provides Business Update

May 2, 2023

BioCryst Presents New Long-term Data Demonstrating Consistently High Attack-free Status Among Hereditary Angioedema Patients with ORLADEYO® (berotralstat)

April 26, 2023

BioCryst to Report First Quarter 2023 Financial Results on May 3

April 18, 2023

BioCryst Refinances Existing Debt with $450 Million Financing Commitment from Pharmakon

April 17, 2023

BioCryst Appoints Dr. Nancy Hutson as Chair of the Board

March 30, 2023

BioCryst Celebrates Bob Ingram’s Contributions to the Company’s Success

March 28, 2023

CADTH Recommends Reimbursement for BioCryst’s ORLADEYO® (berotralstat) for the Routine Prevention of Attacks in Hereditary Angioedema Patients in Canada

March 7, 2023

BioCryst Presents New Long-term and Real-world Data Demonstrating Sustained Reductions in Hereditary Angioedema Attack Rates and Improvement in Quality of Life with ORLADEYO® (berotralstat)

February 23, 2023

BioCryst Reports Fourth Quarter and Full Year 2022 Financial Results and Upcoming Key Milestones

February 20, 2023

BioCryst to Report Fourth Quarter 2022 Financial Results on February 21

February 6, 2023

BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting

February 2, 2023

BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema

January 25, 2023

BioCryst Selects Swixx BioPharma as Commercial Partner for ORLADEYO® (berotralstat) in Central and Eastern Europe

January 22, 2023

BioCryst Reports Initial Clinical Data with Oral Factor D Inhibitor BCX10013 Supporting Development as a Once-daily Treatment for Complement-mediated Diseases

January 8, 2023

BioCryst Announces Preliminary Full Year 2022 ORLADEYO® (berotralstat) Net Revenue and Provides Full Year 2023 ORLADEYO Net Revenue Guidance

January 8, 2023

BioCryst to Present at 41st Annual J.P. Morgan Healthcare Conference

January 3, 2023

Calls in 2023

Decks in 2023